pancreatic neoplasms/tyrosine

FIELD OF INVENTION This invention relates to methods and compositions for the diagnosis, classification, and treatment of cancer. More specifically, this invention is a method of identifying cancer using novel protein phosphorylation status. BACKGROUND OF THE INVENTION The intracellular tyrosine

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the field of biochemical pathways. More particularly, it concerns the pathways connecting DNA damage and phosphorylation by tyrosine kinaseses. 2. Description of the Related Art Current treatment methods

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 11, 2016, is named OTJ_009US_Sequence.txt and is 27,712 bytes in

TECHNICAL FIELD OF THE INVENTION This invention is related to the area of tumor immunology. In particular, it relates to highly immunogenic proteins found on tumor cells. BACKGROUND OF THE INVENTION Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignant disease with a median survival of

FIELD OF THE INVENTION The invention relates to 6,7-dialkoxy quinazoline derivatives, or pharmaceutically acceptable salts thereof, which possess anti-cancer activity and hence useful in methods of treatment in humans. The invention also relates to processes for the manufacture of the said

FIELD This disclosure concerns inhibitors of the T-cell specific alternative p38 activation pathway and their use for the treatment of p38-associated diseases, such as autoimmune and inflammatory disorders, including inflammatory cancers. In particular, this disclosure concerns Gadd45.alpha.

FIELD OF THE INVENTION The invention relates to 6,7-dialkoxy quinazoline derivatives, or pharmaceutically acceptable salts thereof, which possess anti-cancer activity and hence useful in methods of treatment in humans. The invention also relates to processes for the manufacture of the said

FIELD OF THE INVENTION The present invention is directed to novel pyrimido compounds that inhibit the Src family of non-receptor tyrosine kinases (SFKs). These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer,

The present invention relates to a method for treating patients afflicted with cancer, wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine